.png)
Partnerships spanning foundational CRISPR technology, platform development and the urgent care channel.

A strategic agreement announced alongside a Series A extension, together totaling up to $25 million to advance the CRISPR-based platform. It is an important step in validating a target-amplification-free approach to the unmet needs of decentralized molecular diagnostics.

A health system management company serving the urgent care channel. UCPMM builds, runs and convenes modern US urgent care, with engagements in all 50 states.
UCPMM supports the platform's introduction into its operator network and the broader urgent care community, led by VedaBio's own commercial team, with wider distribution added later as the installed base grows.

A non-exclusive license for select CRISPR-based technologies in diagnostic applications, complementing VedaBio’s own large portfolio of wholly owned intellectual property.
VedaBio’s platform is in development. It is investigational, has not been cleared, authorized or approved by the U.S. Food and Drug Administration, and is not available for sale.
We welcome conversations with strategic partners, health systems, urgent-care operators and value-add investors who want to bring molecular testing closer to the patient.